Impaired clonogenic growth of myelodysplastic bone marrow progenitors in vitro is irrelevant to their apoptotic state

Leukemia Research

Volumn 28, Issue 8, 2004, Pages 805-812

  Michalopoulou, Sotiria ^a   Micheva, Ilina ^a   Kouraklis Symeonidis, Alexandra ^a   Kakagianni, Theodora ^a   Symeonidis, Argiris ^a   Zoumbos, Nicholas C ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

acute myeloid leukemia; AML; BFU E; BMMC; bone marrow mononuclear cells; bovine serum albumin; BSA; burst forming unit erythroid; CFU E; CFU GM; chronic myelomonocytic leukemia; CMML; colony forming unit granulocyte macrophage; colony forming unit erythroid

Indexed keywords

CD34 ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CULTURE; CELL GROWTH; CLINICAL ARTICLE; CLONOGENESIS; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A5; ANTIGENS, CD34; APOPTOSIS; BONE MARROW CELLS; CELLS, CULTURED; FEMALE; HEMATOPOIESIS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; STEM CELLS; TUMOR STEM CELL ASSAY;

EID: 2942627706     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.12.004     Document Type: Article

References (48)

1. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia. 7:1993;144-146
2. Yoshida Y., Stephenson J., Mufti G.J. Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Int. J. Hematol. 57:1993;87-97
3. Greenberg P.L. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res. 22:1998;1123-1136
4. Clark D.M., Lampert I.A. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leuk Lymph. 2:1990;415-418
5. Raza A., Gezer S., Mundle S., Gao X.Z., Alvi S., Borok R., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 86:1995;268-276
6. Bogdanovic A.D., Trpinac D.P., Jankovic G.M., Bumbasirevic V.Z., Obradovic M., Colovic M.D. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia. 11:1997;656-659
7. Parker J.E., Fishlock K.L., Mijovic A., Czepulkowski B., Pagliuca A., Mufti G.J. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro-versus anti-apoptotic bcl-2-related proteins. Br. J. Haematol. 103:1998;1075-1082
8. Tsoplou P., Kouraklis-Symeonidis A., Thanopoulou E., Zikos P., Orphanos V., Zoumbos N.C. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes. Leukemia. 13:1999;1554-1563
9. Matthes T.W., Meyer G., Samii K., Beris P. Increased apoptosis in acquired sideroblastic anemia. Br. J. Haematol. 111:2000;843-852
10. Lepelley P., Campergue L., Grardel N., Preudhomme C., Cosson A., Fenaux P. Is apoptosis a massive process in myelodysplastic syndromes? Br. J. Haematol. 95:1996;368-371
11. Choi J.W. Apoptotic rate varies with detection methods in myelodysplastic syndromes: impact of method selection. Eur. J. Hematol. 69:2002;62-63
12. Dar S., Mundle S., Andric T., Qawi H., Shetty V., Reza S., et al. Biological characteristics of myelodysplastic syndrome patients who demonstrate high versus no intramedullary apoptosis. Eur. J. Hematol. 62:1999;90-94
13. Irvine A.E., Magill M.K., Somerville L.E., McMullin M.F. Spontaneous intramedullary apoptosis is present in disorders other than myelodysplasia. Exp. Hematol. 26:1998;435-439
14. Yuan J., Angelucci E., Lucarelli G., Aljurf M., Snyder L.M., Kiefer C.R., et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia). Blood. 82:1993;374-377
15. Yoshida Y., Kawabata H., Anzai N., Tohyama K. Apoptosis as a cell biological abnormality in myelodysplasia. Pathol. Biol. 45:1997;573-578
16. Philpott N.J., Scopes J., Marsh J.C., Gordon-Smith E.C., Gibson F.M. Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Exp. Hematol. 23:1995;1642-1648
17. Koh P.S., Hughes G.C., Faulkner G.R., Keeble W.W., Bagby R.C. The Fanconi anemia group C gene product modulates apoptotic response to tumor necrosis factor-α and fas-ligand but does not suppress expression of the to tumor necrosis factor receptor superfamily. Exp. Hematol. 27:1999;1-8
18. Perdahl E.B., Naprstek B.L., Wallace W.C., Lipton J.M. Erythroid failure in Diamond-Blackfan anemia is characterized by apoptosis. Blood. 83:1994;645-650
19. - cells to undergo apoptosis in myelodysplastic marrows. Int. J. Hematol. 69:1999;152-159
20. Pecci A., Travaglino E., Klersy C., Invernizzi R. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow. Acta. Hematol. 109:2003;29-34
21. Ruutu T., Partanen S., Lintula R., Teerenhovi L., Knuutila S. Erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Scand. J. Haematol. 32:1984;395-402
22. Ohmori M., Ohmori S., Ueda Y., Yoshida Y., Okuma M. Ineffective hemopoiesis in the myelodysplastic syndromes (MDS) as studied by daily in situ observation. Int. J. Cell Cloning. 9:1991;521-530
23. Dan K., An E., Futaki M., Inokuchi K., Gomi S., Yamada T., et al. Megakaryocyte, erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Acta Haematol. 89:1993;113-118
24. Flores-Figueroa E., Gutierrez-Espindola G., Guerrero-Rivera S., Pizzuto-Chavez J., Mayani H. Hematopoietic progenitor cells from patients with myelodysplastic syndromes: in vitro colony growth and long-term proliferation. Leuk Res. 23:1999;385-394
25. McMullin M.F., Buckley O., Magill M.K., Irvine A.E. Long-term bone marrow culture profiles in patients with myelodysplastic syndromes are not explicable by defective apoptosis. Leuk Res. 22:1998;735-740
26. Koopman G., Reutelingsperger C.P.M., Kuijten G.A.M., Keehnen R.M.J., Pals S.T., Van Oers M.H.J. Annexin-V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84:1994;1415-1420
27. Petit P.X., Zamzami N., Vayssière J.-L., Mignotte B., Kroemer G., Castedo M. Implication of mitochondria in apoptosis. Mol. Cell Biochem. 174:1997;185-188
28. Rutella S., Rumi C., Pierelli L., Morosetti R., Sica S., Bonanno G., et al. Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Exp. Hematol. 28:2000;612-625
29. Westwood N.B., Mufti G.J. Apoptosis in the myelodysplastic syndromes. Curr. Hematol. Rep. 2:2003;186-192
30. Saberwal G., Broderick E., Jansen I., Shetty V., Alvi S., Lisak L., et al. Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes. J. Hematother Stem. Cell Res. 12:2003;443-450
31. Darzynkiewicz Z, Bedner E, Traganos F. Difficulties and pitfalls in analysis of apoptosis, Methods Cell Biol 2001;63:527-546.
32. Stahelin B.J., Marti U., Solioz M., Zimmermznn H., Reichen J. False positive staining in the TUNEL assay to detect apoptosis in liver and intestine is caused by endogenous nucleases and inhibited by diethyl pyrocarbonate. Mol. Pathol. 51:1998;204-208
33. Kockx M.M., Muhring J., Knaapen M.W., de Meyer G.R. RNA synthesis and splicing interferes with DNA in situ end labelling techniques used to detect apoptosis. Am. J. Pathol. 152:1998;885-888
34. Grasl-Kraupp B., Ruttkay-Nedecky B., Koudelka H., Bukowska K., Bursch W., Schulte-Hermann R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate between apoptosis, necrosis and autolytic cell death: a cautionary note. Hepatology. 21:1995;1465-1468
35. Darzynkiewicz Z., Bedner E., Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol. 38:2001;179-193
36. Yoshida Y., Anzai N., Kawabata H. Apoptosis in myelodysplasia: a paradox or a paradigm. Leuk Res. 19:1995;887-891
37. Denecker G., Dooms H., Van Loo G., Vercammen D., Grooten J., Fiers W., et al. Phosphatidyl serine exposure during apoptosis precedes release of cytochrome c and decrease in mitochondrial transmembrane potential. FEBS Lett. 465:2000;47-52
38. Roy S., Nicholson D.W. Cross-talk in cell death signaling. J. Exp. Med. 192:2000;F21-F25
39. Vaughan A.T.M., Betti C.J., Villalobos M.J. Surviving apoptosis. Apoptosis. 7:2002;173-177
40. Hoeppner D.J., Hengartner M.O., Schnabel R. Engulfment genes cooperate with ced-3 to promote cell death in Caenorhabditis elegans. Nature. 412:2001;202-206
41. Reddien PW, Cameron S, Horvitz HR. Phagocytosis promotes programmed cell death in C. elegans, Nature 2001: 412-198-202.
42. Hammill A.K., Uhr J.W., Scheuermann R.H. Annexin-V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp. Cell Res. 251:1999;16-21
43. Span L.F.R., Pennings A.H.M., Vierwinden G., Boezeman J.B.M., Raymakers R.A.P., de Witte T. The dynamic process of apoptosis analyzed by flow cytometry using Annexin-V/propidium iodide and a modified in situ end labeling technique. Cytometry. 47:2002;24-31
44. Bouscary D., Chen Y.L., Guesnu M., Picard F., Viguier F., Lacombe C., et al. Activity of the caspase-3/CPP32 enzyme is increased in "early- stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp Hematol. 28:2000;784-791
45. Bowen D.T., Denzlinger C., Brugger W., Culligan D., Gelly K., Adlakha S., et al. Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients. Br. J. Haematol. 103:1998;785-787
46. Tefferi A., Elliot M.A., Steensma D.P., Hook C.C., Dispenzieria A., Hanson C.A., et al. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res. 25:2001;183-185
47. Nemunaitis J., Rosenfeld C., Getty L., Boegel F., Meyer W., Jennings L.W., et al. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial. Am. J. Clin. Oncol. 18:1995;189-193
48. Rosenfeld C., Bedell C. Pilot study of recombinant human soluble tumor necrosos factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. Leuk Res. 26:2002;721-724